| Literature DB >> 29081926 |
Nektarios Koufopoulos1, Christina Goudeli2, John Syrios3, Evangelos Filopoulos4, Lubna Khaldi1.
Abstract
Mucinous cystadenocarcinoma is an extremely rare variant of primary breast tumor which is histologically similar to mucinous cystadenocarcinoma of the ovary and pancreas. Herein we report a case of a 63 years old woman diagnosed with diverse histological types of non-synchronous rare primary breast tumors, a medullary carcinoma of the right breast and a mucinous cystadenocarcinoma of the left breast. Macroscopically the neoplasm appeared multilocular filled with mucoid material. Under light microscopy the cystic areas were lined by columnar cells with abundant intracellular and extracellular mucin. Solid areas were composed of tall columnar cells with intracellular mucin. Moderate to marked atypia was noticed and tumor cells stained positive for cytokeratin 7 and negative for cytokeratin 20. Moreover tumor cells displayed a basal like immunophenotype expressed as followed: ER negative, PR negative, HER-2 negative, cytokeratin (CK5/6) positive and EGFR positive.Entities:
Keywords: Basal like; Breast; Embryogenesis; Mucinous cystadenocarcinoma
Year: 2017 PMID: 29081926 PMCID: PMC5643878 DOI: 10.4081/rt.2017.7016
Source DB: PubMed Journal: Rare Tumors ISSN: 2036-3605
Figure 1.A) The epithelium is moderately differentiated with single or pseudostratified basal nuclei that present mild atypia with intracellular mucin production. B) Extracellular mucin production in cystadenocarcinoma of the breast.
Reported instances of primary breast mucinous cystadenocarcinomas.
| Case (Ref.) | Age, years | Size, mm | Stage (pTNM) | ER | PR | c-erbB2 | Ki-67, % | Treatment | Follow-up |
|---|---|---|---|---|---|---|---|---|---|
| 13 | 79 | 60 | T3N0M0 | NA | NA | NA | NA | M, | DOR 2 years |
| 21 | 54 | 190 | T4N1M0 | – | – | NA | 40 | M, LND | ANED 24 months |
| 31-Jan | 67 | 23 | T2N0M0 | – | – | NA | 30 | M, LND | ANED 22 months |
| 41 | 9 | 85 | T3N0M0 | – | – | NA | 70 | M, LND, C, R | ANED 11 months |
| 51 | 61 | 8 | T1N0M0 | – | – | NA | 50 | L, LND | NA |
| 62 | 74 | 100 | T3N0M0 | – | NA | NA | 21.8 | M, LND | ANED |
| 74 | 96 | 20 | T2N2M0 | – | – | – | 35 | L, LND | DOR 46 months |
| 85 | 65 | 30 | T2N0M0 | – | – | – | 20.5 | M, LND, C | ANED 8 months |
| 96 | 51 | 40 | T2N0M0 | – | – | NA | NA | L | NA |
| 107 | 55 | 25 | T2N0M0 | – | – | – | 90 | L | ANED 6 months |
| 118 | 52 | 100 | T3N0M0 | + | – | – | NA | M, LND | ANED 24 months |
| 6-May | 61 | 30 | T2N0M0 | – | – | – | NA | M, LND | ANED 6 months |
| 139 | 73 | 45 | T2N0M0 | – | – | 2+ | NA | M, LND | NA |
| 1410 | 65 | 30 | T2N0M0 | – | – | NA | NA | PM, LND | ANED 6 months |
| 157 | 52 | 65 | T3N0M0 | – | – | – | 10 | NA | NA |
| 1611 | 41 | 70, 50, 25 | T3N1M0 | – | – | 50 | M, LND | ANED 24 months | |
| 177 | 59 | 9 | T1N0M0 | – | – | 2+ | 5 | PM, LND, C | ANED 3 months |
| 187 | 62 | 56 | T3N0M0 | – | – | – | NA | M, LND | ANED 5 months |
| 1912 | 55 | 20 | T1N0M0 | – | – | 2+ | 30 | L, LND, C, R | ANED 10 months |
| 2013 | 91 | 75 | T3N0M0 | – | – | – | 40 | M, R | DOR 14 months |
ANED, Alive with no evidence of disease; C, chemotherapy; DOR, died of other reason; ER, estrogen receptor; L, lumpectomy; LND, with lymph node dissection; M, modified radical mastectomy; NA, not available; PM, partial mastectomy; PR, progesterone receptor; R, radiation therapy; TNM, tumor, node, metastasis.